跳至主要内容
临床试验/NCT05302609
NCT05302609终止2 期

Phase II Study: Evaluation of SclerFIX Graft in Scleral Thinning After Exeresis of Tumors of the Ocular Surface

TBF Genie Tissulaire2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2022年7月4日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
发起方
入组人数
17
试验地点
2
主要终点
Rate of tectonic success of the graft at 3 months

研究概览

简要总结

The purpose of this open, multicenter phase II trial is to confirm the tolerance and evaluate the efficacy of the SclerFIX product, an allograft of umbilical cord lining membrane, in reinforcement of scleral thinning in patients who underwent eye tumor exeresis.

详细描述

As scleral graft is forbidden in France, it cannot be used to reinforce the sclera. This study investigational product, SclerFIX, was developed to substitute scleral grafts.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female, aged 18 to 80 years.
  • Patients with risk of perforation or deep loss of substance during surgical removal of a tumor of the ocular surface.
  • Patient with loss of substance < 3cm
  • Patient able to understand, sign and date the informed consent form.
  • Patient who is a member or a beneficiary of a national health insurance plan.

排除标准

  • Pregnant or breastfeeding woman or woman of childbearing age without effective contraception.
  • Patients with uncontrolled infectious risk.
  • Patient with an autoimmune disease.
  • Person deprived of liberty by a judicial or administrative decision.
  • Person under forced psychiatric care.
  • Person admitted to a health or social institution for purposes other than the research.
  • Adult subjected to a legal protection measure or unable to express his / her consent.

研究组 & 干预措施

SclerFIX

Experimental

Patch of umbilical cord lining membrane sutured on top of the scleral defect.

干预措施: SclerFIX (Biological)

结局指标

主要结局

Rate of tectonic success of the graft at 3 months

时间窗: 3 months

The graft will be considered successful at 3 months if the curvature of the eye is respected without thinning, i.e., in the absence of edema, ulceration and loss of substance (thickness of the grafted area/thickness of the adjacent surface \> 80%). The scleral thickness will be determined from images obtained by optical coherence tomography (OCT).

次要结局

  • Absence of inflammatory reactions and good local tolerance of the implant(15 days, 1 month, 3 months)
  • Evaluation of the visual acuity(15 days, 1 month, 3 months)
  • Evaluation of the eye pressure(15 days, 1 month, 3 months)

研究者

发起方
TBF Genie Tissulaire
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验